Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

880180P

Avanti

C16 PEG2000 Ceramide

Avanti Research™ - A Croda Brand 880180P, powder

Synonym(s):

N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

CAS Number:
212116-78-4
UNSPSC Code:
12352211
NACRES:
NA.25

form

powder

packaging

pkg of 1 × 1 g (880180P-1g)
pkg of 1 × 200 mg (880180P-200mg)
pkg of 1 × 25 mg (880180P-25mg)
pkg of 1 × 500 mg (880180P-500mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 880180P

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCCCC)=O)COC(CCC(OOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O.C=C

General description

C16 PEG2000 Ceramide, also known as N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}, is a polyethylene glycol (PEG)-ylated ceramide.

Application

C16 PEG2000 Ceramide or N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}, has been used in lipidoid/protein nanocomplex preparation. It has also been used in the preparation of SNALPs (stable nucleic acid lipid particles).

Packaging

20 mL Clear Glass Screw Cap Vial (880180P-1g)
20 mL Clear Glass Screw Cap Vial (880180P-500mg)
5 mL Amber Glass Screw Cap Vial (880180P-200mg)
5 mL Amber Glass Screw Cap Vial (880180P-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Xiaoying Wang et al.
Journal of controlled release : official journal of the Controlled Release Society, 263, 39-45 (2017-02-06)
Developing safe and effective nanosystems to deliver active and therapeutic proteins to targeted cells and organs is an important tool for many biomedical applications. We present here a simple and efficient strategy for this purpose: delivering hyaluronic acid (HA)-modified RNase
Kaushik Thanki et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 120, 22-33 (2017-08-02)
Safety and efficacy of therapeutics based on RNA interference, e.g., small interfering RNA (siRNA), are dependent on the optimal engineering of the delivery technology, which is used for intracellular delivery of siRNA to the cytosol of target cells. We investigated
Kaushik Thanki et al.
Pharmaceutical research, 36(3), 37-37 (2019-01-10)
Antisense oligonucleotides (ASOs) are promising therapeutics for specific modulation of cellular RNA function. However, ASO efficacy is compromised by inefficient intracellular delivery. Lipid-polymer hybrid nanoparticles (LPNs) are attractive mediators of intracellular ASO delivery due to favorable colloidal stability and sustained

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service